MCID: SCL017
MIFTS: 39

Sclerosing Hemangioma

Categories: Cancer diseases, Skin diseases

Aliases & Classifications for Sclerosing Hemangioma

MalaCards integrated aliases for Sclerosing Hemangioma:

Name: Sclerosing Hemangioma 12 15 73
Cutaneous Fibrous Histiocytoma 73
Sclerosing Haemangioma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:495
SNOMED-CT 68 72079004

Summaries for Sclerosing Hemangioma

MalaCards based summary : Sclerosing Hemangioma, also known as cutaneous fibrous histiocytoma, is related to pulmonary sclerosing hemangioma and hemangioma. An important gene associated with Sclerosing Hemangioma is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are Arf6 trafficking events and Cell adhesion_Cadherin-mediated cell adhesion. The drugs Mechlorethamine and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include lung, skin and liver.

Wikipedia : 76 Benign fibrous histiocytomas (also known as dermal dendrocytoma,dermatofibroma,fibrous... more...

Related Diseases for Sclerosing Hemangioma

Diseases related to Sclerosing Hemangioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 239)
# Related Disease Score Top Affiliating Genes
1 pulmonary sclerosing hemangioma 32.5 CHGA CTNNB1 CTNND1 KRT7 NKX2-1 SFTPB
2 hemangioma 31.3 CHGA NKX2-1 SFTPB SYP
3 hemangioma of lung 30.6 NKX2-1 SFTPB
4 carcinoid syndrome 30.1 CHGA SYP
5 bile duct cystadenocarcinoma 29.8 KRT7 MUC1
6 cystadenocarcinoma 29.5 KRT7 MUC1 PGR
7 cavernous hemangioma 29.4 KRT7 MUC1 NKX2-1 SYP
8 neuroendocrine tumor 29.4 CHGA KRT7 NKX2-1 SYP
9 papillary adenocarcinoma 29.3 KRT7 MUC1 NKX2-1 PGR
10 fibrous histiocytoma 11.5
11 cutaneous fibrous histiocytoma 11.5
12 gastric cardia carcinoma 10.2 CHGA MUC1
13 papilloma of choroid plexus 10.2 MUC1 SYP
14 rhabdoid tumor predisposition syndrome 1 10.2 MUC1 SYP
15 optic nerve glioma 10.2 MUC1 SYP
16 cerebral primitive neuroectodermal tumor 10.2 MUC1 SYP
17 neurofibroma 10.2 MUC1 SYP
18 subependymal giant cell astrocytoma 10.2 NKX2-1 SYP
19 endocrine organ benign neoplasm 10.2 CHGA SYP
20 malignant pheochromocytoma 10.2 CHGA SYP
21 central neurocytoma 10.2 CHGA SYP
22 cranial nerve malignant neoplasm 10.2 CHGA SYP
23 olfactory neuroblastoma 10.2 CHGA SYP
24 ganglioneuroma 10.2 CHGA SYP
25 pleomorphic xanthoastrocytoma 10.2 CHGA SYP
26 ganglioglioma 10.2 CHGA SYP
27 tanycytic ependymoma 10.2 CHGA SYP
28 papillary ependymoma 10.2 CHGA SYP
29 cerebellar liponeurocytoma 10.2 CHGA SYP
30 cervix small cell carcinoma 10.2 CHGA SYP
31 non-functioning pancreatic endocrine tumor 10.2 CHGA SYP
32 binswanger's disease 10.2 CHGA SYP
33 pilomatrixoma 10.2 CTNNB1 MUC1
34 lobular neoplasia 10.2 CTNNB1 MUC1
35 sinonasal undifferentiated carcinoma 10.2 MUC1 SYP
36 epithelioid malignant peripheral nerve sheath tumor 10.2 CHGA MUC1
37 papillary tumor of the pineal region 10.2 MUC1 SYP
38 polymorphous low-grade adenocarcinoma 10.2 CTNNB1 MUC1
39 ureter small cell carcinoma 10.2 CHGA SYP
40 esophageal neuroendocrine tumor 10.2 CHGA SYP
41 urinary bladder small cell neuroendocrine carcinoma 10.2 CHGA SYP
42 ovarian large-cell neuroendocrine carcinoma 10.2 CHGA SYP
43 auditory system cancer 10.2 CHGA SYP
44 adenoma of the pancreas 10.2 CHGA SYP
45 acinar cell cystadenocarcinoma 10.2 CHGA SYP
46 peritoneal serous adenocarcinoma 10.2 CHGA SYP
47 cellular ependymoma 10.2 CHGA SYP
48 gallbladder small cell carcinoma 10.2 CHGA SYP
49 primary hepatic neuroendocrine carcinoma 10.2 CHGA SYP
50 clear cell ependymoma 10.2 MUC1 SYP

Graphical network of the top 20 diseases related to Sclerosing Hemangioma:



Diseases related to Sclerosing Hemangioma

Symptoms & Phenotypes for Sclerosing Hemangioma

Drugs & Therapeutics for Sclerosing Hemangioma

Drugs for Sclerosing Hemangioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 110)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 51-75-2 4033
2
Ifosfamide Approved Phase 3,Phase 2,Phase 1,Not Applicable 3778-73-2 3690
3
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
4
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
5
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
6
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
7
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 6055-19-2, 50-18-0 2907
8
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
9
Epirubicin Approved Phase 3 56420-45-2 41867
10
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
11
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
12
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1,Not Applicable 31703
13
Isophosphamide mustard Phase 3,Phase 2,Phase 1,Not Applicable 0
14 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
15 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
16 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
17 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
18 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
19 Anti-Infective Agents Phase 3,Phase 2,Phase 1
20 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2
21 Immunologic Factors Phase 3,Phase 2,Phase 1
22 Etoposide phosphate Phase 3,Phase 2
23 Antimitotic Agents Phase 3,Phase 2,Phase 1
24 Antirheumatic Agents Phase 3,Phase 2,Phase 1
25 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
26 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
27
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
28
Indinavir Approved Phase 2 150378-17-9 5362440
29
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
30
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
31
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
32
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750
33
Bevacizumab Approved, Investigational Phase 2 216974-75-3
34
Docetaxel Approved, Investigational Phase 2,Phase 1 114977-28-5 148124
35
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
36
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
37
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
38
Paclitaxel Approved, Vet_approved Phase 1, Phase 2,Phase 2 33069-62-4 36314
39
Sirolimus Approved, Investigational Phase 1, Phase 2,Phase 2 53123-88-9 46835353 6436030 5284616
40
Everolimus Approved Phase 1, Phase 2,Phase 2 159351-69-6 6442177
41
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2,Phase 2 22916-47-8 4189
42
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
43
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
44
Nivolumab Approved Phase 2,Phase 1 946414-94-4
45
Mesna Approved, Investigational Phase 2,Not Applicable 3375-50-6 598
46 Olaratumab Approved, Investigational Phase 2 1024603-93-7
47
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
48
leucovorin Approved Phase 2 58-05-9 6006 143
49
Methotrexate Approved Phase 2 59-05-2, 1959-05-2 126941
50
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938

Interventional clinical trials:

(show top 50) (show all 72)
# Name Status NCT ID Phase Drugs
1 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Unknown status NCT01344018 Phase 3
3 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
4 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
5 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
6 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
7 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
8 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
9 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
10 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
11 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
12 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Suspended NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
13 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
14 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
15 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
16 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
17 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2 imatinib mesylate
18 Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2 Sunitinib Malate (SU011248)
19 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
20 Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes Completed NCT00887809 Phase 2 gemcitabine;docetaxel;bevacizumab
21 Bevacizumab and Radiation Therapy for Sarcomas Completed NCT00356031 Phase 2 Bevacizumab
22 Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung Completed NCT00503295 Phase 2
23 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
24 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
25 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
26 Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors Completed NCT01962103 Phase 1, Phase 2 nab-paclitaxel;nab-paclitaxel
27 Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma Completed NCT00085475 Phase 2 imatinib mesylate
28 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma Completed NCT00949325 Phase 1, Phase 2 temsirolimus (Torisel) plus liposomal doxorubicin (Doxil)
29 Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00064220 Phase 2 soblidotin
30 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
31 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
32 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
33 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
34 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2 brostallicin
35 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2 exatecan mesylate
36 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
37 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
38 Trial of Dasatinib in Advanced Sarcomas Completed NCT00464620 Phase 2 Dasatinib
39 Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma Recruiting NCT03123276 Phase 1, Phase 2 Pembrolizumab;Gemcitabine
40 Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma Recruiting NCT03307616 Phase 2 Nivolumab;Ipilimumab
41 Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma Recruiting NCT01883518 Phase 1, Phase 2
42 Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma Recruiting NCT03190174 Phase 1, Phase 2 Nab-Rapamycin
43 Hypofractionated Radiotherapy With Sequential Chemotherapy in Primary Unresectable or Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Recruiting NCT03651375 Phase 2 Sequential chemotherapy - 3 courses of AI
44 Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin;Olaratumab
45 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
46 A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma Active, not recruiting NCT00667342 Phase 2 Cisplatin;Doxorubicin;Methotrexate;Ifosfamide;etoposide
47 Gemcitabine, Cisplatin, and Abraxane in Advanced Biliary Cancers Active, not recruiting NCT02392637 Phase 2 Abraxane (Nab-Paclitaxel);Cisplatin;Gemcitabine
48 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Active, not recruiting NCT02601209 Phase 1, Phase 2 Pazopanib Hydrochloride;Sapanisertib
49 Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery Suspended NCT02923778 Phase 2
50 Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery Suspended NCT02500797 Phase 2

Search NIH Clinical Center for Sclerosing Hemangioma

Genetic Tests for Sclerosing Hemangioma

Anatomical Context for Sclerosing Hemangioma

MalaCards organs/tissues related to Sclerosing Hemangioma:

41
Lung, Skin, Liver, Thyroid, Kidney, Lymph Node, Thymus

Publications for Sclerosing Hemangioma

Articles related to Sclerosing Hemangioma:

(show top 50) (show all 170)
# Title Authors Year
1
<sup>18</sup>F-FDG PET/CT characteristics of pulmonary sclerosing hemangioma vs. pulmonary hamartoma. ( 29930720 )
2018
2
Hepatic Sclerosing Hemangioma with Predominance of the Sclerosed Area Mimicking a Biliary Cystadenocarcinoma. ( 30402303 )
2018
3
Pneumocytoma (sclerosing hemangioma), a potential pitfall. ( 28398699 )
2017
4
Pulmonary sclerosing hemangioma with a rare symptom: A case report and review of the literature. ( 28357098 )
2017
5
Sclerosing hemangioma of the lung showing strong FDG avidity on PET scan: Case report and review of the current literature. ( 27222778 )
2016
6
Preoperative Diagnosis in 46 Cases of Pulmonary Sclerosing Hemangioma. ( 27231179 )
2016
7
Co-occurrence of bronchial papilloma and pulmonary sclerosing hemangioma in a male. ( 27812454 )
2016
8
Whole-exome sequencing identifies recurrent AKT1 mutations in sclerosing hemangioma of lung. ( 27601661 )
2016
9
Clinical case report: Sclerosing hemangioma of the liver, a rare but great mimicker. ( 27257450 )
2016
10
Pulmonary Hilar Tumor: An Unusual Presentation of Sclerosing Hemangioma. ( 27761142 )
2016
11
Sclerosing hemangioma: A diagnostic dilemma in fine needle aspiration cytology. ( 27168758 )
2016
12
Ectopic ACTH syndrome caused by pulmonary carcinoid tumor mimicking long-standing sclerosing hemangioma. ( 26828249 )
2016
13
Bone metastasis in pulmonary sclerosing hemangioma. ( 26552471 )
2015
14
Multiple hepatic sclerosing hemangioma mimicking metastatic liver tumor successfully treated by laparoscopic surgery: Report of a case. ( 25679307 )
2015
15
Incidental finding of a sclerosing hemangioma in a Caucasian woman. ( 26193226 )
2015
16
Sclerosing hemangioma of the lung. ( 26223076 )
2015
17
Sclerosing hemangioma of the lung mimicking pulmonary metastasis. ( 25762452 )
2015
18
The significance of p40 expression in sclerosing hemangioma of lung. ( 25130377 )
2014
19
Pulmonary sclerosing hemangioma with lymph node metastasis: A case report and literature review. ( 24944657 )
2014
20
Pulmonary sclerosing hemangioma: a unique epithelial neoplasm of the lung (report of 26 cases). ( 23587094 )
2013
21
Diagnosis of sclerosing hemangioma of lung: don't rely on fine-needle aspiration cytology diagnosis alone. ( 24518736 )
2013
22
Unusual coexistence of pulmonary sclerosing hemangioma and pericardial cyst. ( 24887810 )
2013
23
Cytologic features of sclerosing hemangioma of the lung on crush preparations. ( 21710650 )
2013
24
A rare tumor of the lung: pulmonary sclerosing hemangioma (pneumocytoma). ( 23290153 )
2013
25
Histogenesis of pulmonary sclerosing hemangioma and significance of P63 expression. ( 23910931 )
2013
26
18F-FDG PET/CT features of pulmonary sclerosing hemangioma. ( 22291338 )
2013
27
A sclerosing hemangioma of the liver. ( 24459649 )
2013
28
Synchronous occurrence of breast cancer and pulmonary sclerosing hemangioma: management and review of the literature. ( 23838116 )
2013
29
Pneumocytoma (formerly known as sclerosing hemangioma of the lung): a rare cause of chest pain. ( 23380035 )
2013
30
Metastasizing "benign" cutaneous fibrous histiocytoma: a clinicopathologic analysis of 16 cases. ( 23426120 )
2013
31
Pulmonary sclerosing hemangioma presenting with dense spindle stroma cells: a potential diagnostic pitfall. ( 23227905 )
2012
32
A case of pulmonary sclerosing hemangioma with low (18)FDG uptake in PET. ( 22740968 )
2012
33
Treatment of 28 patients with sclerosing hemangioma (SH) of the lung. ( 22515818 )
2012
34
In pulmonary sclerosing hemangioma expression of I^-catenin, Axin, and C-myc differs between the two cell types. ( 22614067 )
2012
35
Fine-needle aspiration diagnosis of sclerosing hemangioma (pneumocytoma): Report of a case and review of the literature. ( 22645055 )
2012
36
Sclerosing hemangioma of the lung manifesting as a cystic lesion with an air-fluid level. ( 22832056 )
2012
37
Pulmonary sclerosing hemangioma: report of two cases. ( 22943472 )
2012
38
Pulmonary sclerosing hemangioma with pleural dissemination: report of a case. ( 21264765 )
2011
39
A case of sclerosing hemangioma forming a pedunculated mass. ( 21881332 )
2011
40
Sclerosing hemangioma in the liver. ( 22102394 )
2011
41
Determination of clonal status of pulmonary sclerosing hemangioma with X-chromosome inactivation mosaicism and polymorphism of phosphoglycerate kinase and androgen receptor genes. ( 20422318 )
2011
42
Coexistence of pulmonary sclerosing hemangioma and primary adenocarcinoma in the same nodule of lung. ( 21599956 )
2011
43
Pulmonary sclerosing hemangioma: pitfalls in management. ( 21471259 )
2011
44
Comparison of genetic and epigenetic alterations at 11 tumor suppressor loci in pulmonary sclerosing hemangioma and adenocarcinoma. ( 21649526 )
2011
45
A case of pulmonary sclerosing hemangioma surrounded by giant cystic change on high-resolution computed tomography. ( 20634757 )
2011
46
F-18 FDG PET/CT in evaluation of pulmonary sclerosing hemangioma. ( 21467848 )
2011
47
Microscopic sclerosing hemangioma diagnosed by histopathological examination after lung cancer surgery. ( 21881377 )
2011
48
Pulmonary sclerosing hemangioma in a 21-year-old male with metastatic hereditary non-polyposis colorectal cancer: report of a case. ( 21645337 )
2011
49
Surgery for Pulmonary Sclerosing Hemangioma: Lobectomy versus Limited Resection. ( 22263122 )
2011
50
Large masses with diffuse calcification: pulmonary sclerosing hemangioma. ( 20732478 )
2010

Variations for Sclerosing Hemangioma

Expression for Sclerosing Hemangioma

Search GEO for disease gene expression data for Sclerosing Hemangioma.

Pathways for Sclerosing Hemangioma

GO Terms for Sclerosing Hemangioma

Cellular components related to Sclerosing Hemangioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 catenin complex GO:0016342 9.26 CTNNB1 CTNND1
2 postsynaptic density, intracellular component GO:0099092 9.16 CTNNB1 CTNND1
3 presynaptic active zone cytoplasmic component GO:0098831 8.96 CTNNB1 CTNND1
4 Schaffer collateral - CA1 synapse GO:0098685 8.8 CTNNB1 CTNND1 SYP

Biological processes related to Sclerosing Hemangioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 adherens junction organization GO:0034332 9.16 CTNNB1 CTNND1
2 epithelial tube branching involved in lung morphogenesis GO:0060441 8.96 CTNNB1 NKX2-1
3 entry of bacterium into host cell GO:0035635 8.62 CTNNB1 CTNND1

Sources for Sclerosing Hemangioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....